A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
a study on Multiple Myeloma
Multiple Myeloma Neoplasms, Plasma Cell Pomalidomide Daratumumab Talquetamab Teclistamab
Lead Scientist at UCSF
- Thomas Martin
Professor, Medicine. Authored (or co-authored) 52 research publications.
- accepting new patients
- Start Date
- Completion Date
- Janssen Research & Development, LLC
- To learn how to participate in this trial please click here.
- Phase 1
- Study Type
- Last Updated